Verrica Pharmaceuticals (VRCA) Non-Current Debt (2020 - 2025)
Verrica Pharmaceuticals (VRCA) posted quarterly Non-Current Debt of $21.6 million for Q3 2025, down 50.08% year-over-year from $43.3 million in Q3 2024, and down 12.04% quarter-over-quarter from $24.6 million in Q2 2025.
Verrica Pharmaceuticals (VRCA) Non-Current Debt (2020 - 2025) Analysis & Trends
Verrica Pharmaceuticals' Non-Current Debt history runs 4 years deep, the most recent figure standing at $21.6 million for Q3 2025.
- In Q3 2025, Non-Current Debt fell 50.08% year-over-year to $21.6 million; the TTM figure through Sep 2025 stood at $21.6 million (down 50.08% YoY), while the FY2024 annual figure was $31.0 million, down 27.73% from the prior year.
- Non-Current Debt for Q3 2025 stood at $21.6 million, down from $24.6 million in the prior quarter.
- The five-year high for Non-Current Debt was $43.3 million in Q3 2024, with the low at $21.6 million in Q3 2025.
- The 3-year median for Non-Current Debt is $42.4 million (2023), against an average of $35.5 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt grew 2.13% in 2024, then tumbled 50.08% in 2025.
- Verrica Pharmaceuticals' Non-Current Debt stood at $42.9 million in 2023, then declined by 27.73% to $31.0 million in 2024, then plunged by 30.22% to $21.6 million in 2025.
- Business Quant data shows VRCA's Non-Current Debt at $21.6 million in Q3 2025, $24.6 million in Q2 2025, and $27.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 8.96 Bn |
| 10 | Verrica Pharmaceuticals | 102.55 Mn | 91.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 21.62 Mn |
| Jun 30, 2025 | 24.58 Mn |
| Mar 31, 2025 | 27.81 Mn |
| Dec 31, 2024 | 30.98 Mn |
| Sep 30, 2024 | 43.31 Mn |
| Jun 30, 2024 | 42.75 Mn |
| Mar 31, 2024 | 42.85 Mn |
| Dec 31, 2023 | 42.87 Mn |
| Sep 30, 2023 | 42.40 Mn |
| Mar 31, 2020 | 34.43 Mn |